Stocks Comparison
Caris Life Sciences vs Veracyte: revenue, profit, margins and growth compared
Caris Life Sciences brought in $812M of revenue in fiscal 2025, Veracyte $517.1M in fiscal 2025. Revenue changed by +97.0% at Caris Life Sciences and +16.0% at Veracyte on the year before, so Caris Life Sciences grew faster. Caris Life Sciences kept -8.4% of its revenue as net profit, Veracyte 12.8%. Free cash flow was $66.9M at Caris Life Sciences and $126.6M at Veracyte.
Side by side, latest fiscal year
| CAI | VCYT | |
|---|---|---|
| Fiscal year ended | FY2025 (December 31, 2025) | FY2025 (December 31, 2025) |
| Revenue | $812M | $517.1M |
| Revenue growth | +97.0% | +16.0% |
| Net income | -$68.1M | $66.4M |
| Net margin | -8.4% | 12.8% |
| Free cash flow | $66.9M | $126.6M |
| Free cash flow margin | 8.2% | 24.5% |
| Earnings per share (diluted) | -$3.22 | $0.82 |
| Cash | $796.3M | $362.6M |
| Debt | $378.5M | n/a |
| Price to earnings | n/a | 55.4 |
| Market value | $9B | $3.7B |
| Dividend yield | n/a | n/a |
| Rank by revenue in sector | #161 of 523 · Health care | #190 of 523 · Health care |
Over the years
Questions about Caris Life Sciences and Veracyte
Which is bigger by revenue, Caris Life Sciences or Veracyte?
Caris Life Sciences is bigger by revenue: $812M in fiscal 2025, against $517.1M for Veracyte in fiscal 2025.
Which keeps more of its revenue as profit, Caris Life Sciences or Veracyte?
Caris Life Sciences had a net margin of -8.4% in fiscal 2025; Veracyte had 12.8% in fiscal 2025.
Which grew revenue faster, Caris Life Sciences or Veracyte?
In their latest fiscal years revenue changed by +97.0% at Caris Life Sciences and +16.0% at Veracyte.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.